-
公开(公告)号:US20060281773A1
公开(公告)日:2006-12-14
申请号:US11325965
申请日:2006-01-05
申请人: Jyoti Patel , Qi Shuai , James Link , Jeffrey Rohde , Jurgen Dinges , Bryan Sorensen , Martin Winn , Hong Yong , Vince Yeh
发明人: Jyoti Patel , Qi Shuai , James Link , Jeffrey Rohde , Jurgen Dinges , Bryan Sorensen , Martin Winn , Hong Yong , Vince Yeh
IPC分类号: A61K31/505 , A61K31/401 , A61K31/41 , A61K31/195 , A61K31/277
CPC分类号: C07C233/23 , C07C235/14 , C07C237/24 , C07C255/31 , C07C255/47 , C07C259/16 , C07C311/08 , C07C311/29 , C07C311/46 , C07C311/51 , C07C317/22 , C07C317/30 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D207/48 , C07D213/64 , C07D233/64 , C07D257/04 , C07D261/08
摘要: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
-
2.
公开(公告)号:US20070179186A1
公开(公告)日:2007-08-02
申请号:US11733636
申请日:2007-04-10
申请人: Jeffrey Rohde , Qi Shuai , James Link , Jyoti Patel , Jurgen Dinges , Bryan Sorensen , Hong Yong , Vince Yeh , Ravi Kurukulasuriya
发明人: Jeffrey Rohde , Qi Shuai , James Link , Jyoti Patel , Jurgen Dinges , Bryan Sorensen , Hong Yong , Vince Yeh , Ravi Kurukulasuriya
IPC分类号: A61K31/445 , A61K31/4015 , C07D211/06
CPC分类号: C07D207/277 , C07C233/11 , C07C233/52 , C07C233/58 , C07C233/63 , C07C237/24 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2603/74 , C07D211/78 , C07D213/56 , C07D231/12 , C07D261/08 , C07D333/24
摘要: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme, The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖型 2型糖尿病,胰岛素抵抗,肥胖,脂质障碍,代谢综合征以及由过度糖皮质激素作用介导的其他疾病和病症。
-
3.
公开(公告)号:US20060149070A1
公开(公告)日:2006-07-06
申请号:US11326277
申请日:2006-01-05
申请人: Jeffrey Rohde , Qi Shuai , James Link , Jyoti Patel , Jurgen Dinges , Bryan Sorensen , Hong Yong , Vince Yeh , Ravi Kurukulasuriya
发明人: Jeffrey Rohde , Qi Shuai , James Link , Jyoti Patel , Jurgen Dinges , Bryan Sorensen , Hong Yong , Vince Yeh , Ravi Kurukulasuriya
IPC分类号: C07D211/06
CPC分类号: C07D207/277 , C07C233/11 , C07C233/52 , C07C233/58 , C07C233/63 , C07C237/24 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2603/74 , C07D211/78 , C07D213/56 , C07D231/12 , C07D261/08 , C07D333/24
摘要: The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译: 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶的抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病,胰岛素抵抗,肥胖症,脂质障碍,代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
公开(公告)号:US20090054426A1
公开(公告)日:2009-02-26
申请号:US12195937
申请日:2008-08-21
申请人: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
发明人: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC分类号: A61K31/496 , A61P25/00 , A61K31/5375 , A61K31/445 , A61K31/16
CPC分类号: C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
摘要: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
摘要翻译: 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法,包括注意力缺陷障碍,注意力缺陷多动障碍(ADHD),阿尔茨海默病(AD),轻度认知障碍 老年性痴呆,艾滋病痴呆,神经变性,抑郁和精神分裂症,包括向需要这种治疗的患者施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。
-
公开(公告)号:US08940902B2
公开(公告)日:2015-01-27
申请号:US13554698
申请日:2012-07-20
申请人: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
发明人: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC分类号: C07D211/74 , A61K31/44 , A61K31/495
CPC分类号: C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
摘要: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
摘要翻译: 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法,包括注意力缺陷障碍,注意力缺陷多动障碍(ADHD),阿尔茨海默病(AD),轻度认知障碍 老年性痴呆,艾滋病痴呆,神经退行性疾病,抑郁症和精神分裂症,包括向需要这种治疗的患者施用有效量的11-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。
-
公开(公告)号:US20130059829A1
公开(公告)日:2013-03-07
申请号:US13554698
申请日:2012-07-20
申请人: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
发明人: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC分类号: A61K31/5375 , A61K31/55 , A61K31/551 , A61K31/397 , A61K31/16 , A61P25/28 , A61P25/24 , A61P25/18 , A61P25/22 , A61K31/496 , A61P25/00
CPC分类号: C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
摘要: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
-
公开(公告)号:US20100152179A9
公开(公告)日:2010-06-17
申请号:US12195937
申请日:2008-08-21
申请人: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
发明人: R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC分类号: A61K31/496 , A61P25/00 , A61K31/5375 , A61K31/445 , A61K31/16
CPC分类号: C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
摘要: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
摘要翻译: 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法,包括注意力缺陷障碍,注意力缺陷多动障碍(ADHD),阿尔茨海默病(AD),轻度认知障碍 老年性痴呆,艾滋病痴呆,神经退行性疾病,抑郁症和精神分裂症,包括向需要这种治疗的患者施用有效量的11-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。
-
8.
公开(公告)号:US20080076819A1
公开(公告)日:2008-03-27
申请号:US11697044
申请日:2007-04-05
申请人: Vince Yeh , Ravi Kurukulasuriya , David Madar , James Link
发明人: Vince Yeh , Ravi Kurukulasuriya , David Madar , James Link
IPC分类号: A61K31/40 , A61P3/04 , C07D207/00
CPC分类号: C07D401/14 , C07D207/26 , C07D207/267 , C07D401/12 , C07D403/12
摘要: A compound of formula (I): or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译: 式(I)的化合物或其药学上可接受的盐,前药,前药的盐或其组合。 抑制11-β-羟基类固醇脱氢酶1型酶的方法。 治疗非胰岛素依赖型2型糖尿病,胰岛素抵抗,肥胖症,脂质障碍,代谢综合征等由过度糖皮质激素作用介导的疾病和病症的方法。
-
9.
公开(公告)号:US09303034B2
公开(公告)日:2016-04-05
申请号:US14574775
申请日:2014-12-18
申请人: Agnes Biggart , Fang Liang , Casey Jacob Nelson Mathison , Valentina Molteni , Advait Suresh Nagle , Frantisek Supek , Vince Yeh
发明人: Agnes Biggart , Fang Liang , Casey Jacob Nelson Mathison , Valentina Molteni , Advait Suresh Nagle , Frantisek Supek , Vince Yeh
IPC分类号: A61K31/519 , C07D487/04 , C07D519/00 , C07F5/02 , C07F7/08
CPC分类号: A61K31/519 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D487/04 , C07D519/00 , C07F5/027 , C07F7/0814
摘要: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
摘要翻译: 本发明提供式A化合物或其药学上可接受的盐,互变异构体或立体异构体,其中变量如本文所定义。 本发明还提供了包含这些化合物的药物组合物和使用这些化合物治疗,预防,抑制,改善或消除由寄生虫引起的疾病的病理和/或症状的方法,例如利什曼病,人非洲锥虫病和查加斯 疾病。
-
公开(公告)号:US20150051206A1
公开(公告)日:2015-02-19
申请号:US14241884
申请日:2012-08-29
申请人: Jon Loren , Xiaolin Li , Xiaodong Liu , Valentina Molteni , Juliet Nabakka , Bao Nguyen , Hank Michael James Petrassi , Vince Yeh , Paul Vincent Rucker
发明人: Jon Loren , Xiaolin Li , Xiaodong Liu , Valentina Molteni , Juliet Nabakka , Bao Nguyen , Hank Michael James Petrassi , Vince Yeh , Paul Vincent Rucker
IPC分类号: C07D471/04
CPC分类号: C07D471/04
摘要: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.
摘要翻译: 本发明提供了可用作蛋白激酶抑制剂的化合物及其药物组合物,以及使用这些化合物治疗,改善或预防与异常或失调激酶活性相关的病症的方法。 在一些实施方案中,本发明提供了使用这些化合物治疗,改善或预防涉及c-kit或c-kit和PDGFR(PDGFRα,PDGFR&bgr))激酶的异常活化的疾病或病症的方法。
-
-
-
-
-
-
-
-
-